Close Menu

NEW YORK – Adaptive Biotechnologies said today that it will provide its ClonoSeq assay to Amgen for use in drug development of blood cancer therapies.

Under the global four-year agreement, Adaptive will receive annual development fees, in addition to sequencing payments and regulatory milestones, in exchange for providing ClonoSeq for minimal residual disease (MRD) testing and analysis for ongoing and future clinical trials.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.